For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.co.jp/

Daiichi Pharmaceutical (Beijing) Granted Sales Promotion Permission

Tokyo, February 28, 2007 -DAIICHI SANKYO COMPANY, LIMITED has announced that Daiichi Pharmaceutical (Beijing) Co., Ltd. (head office: Beijing; President: Tsutomu Une), a subsidiary of Daiichi Pharmaceutical Co., Ltd., itself a wholly owned subsidiary of DAIICHI SANKYO, has been granted permission to promote sales of (but not actually sell) pharmaceutical products of its parent company within China. The business permit registration for Daiichi Pharmaceutical (Beijing) has been amended to include this new business in its scope of operations.

 

The amended registration gives approval for the sales promotion of pharmaceuticals sold within China by parent company Daiichi Pharmaceutical,* headquartered in Tokyo. This is the first time that a Japanese company has been granted such permission.

 

Previously, Daiichi Pharmaceutical (Beijing) could only sell and promote products it had manufactured by itself, but the newly granted permission enables it to also promote products imported and sold by Shanghai Sankyo Pharmaceutical Co., Ltd, which had already acquired a medicine management certificate. This will broaden the sales scope of its medical representatives (MR) and should accelerate the synergies within the DAIICHI SANKYO Group's pharmaceutical business in China.

 

Daiichi Pharmaceutical (Beijing) plans to focus its sales promotions on the anti-infectives franchise that includes Cravit® and Tarivid®.

 

* As of April 2007, Daiichi Pharmaceutical Co., Ltd will become DAIICHI SANKYO COMPANY, LIMITED.